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used for dose measurements in the build-up zone for 
megavoltage photon beams. The study focused in ultrathin 
thermoluminescent (TL) detectors with an effective point of 
measurement (EPOM) smaller than 5 mg/cm2, Gafchromic 
films (EPOM~120 mg/cm2 ) and a novel plastic scintillator 
detector (EPOM ~0.8 g/cm2). 
Materials and Methods: Two types of ultrathin LiF:Mg,Cu,P-
based TL dosimeters (MCP-Ns from TLD Poland and TLD-2000F 
from Conqueror Electronics Technology Co. Ltd.), EBT2 
Gafchromic films (Ashland) and an Exradin W1 plastic 
scintillator (Standard Imaging) have been tested against the 
results of a PTW-Freiburg 23392 extrapolation chamber (EC), 
entrance window ~0.7 mg/cm2. The experimental 
measurements were also compared with Monte Carlo dose 
calculations with the PENELOPE/penEasy code. 
All the studied detectors were used to measure the dose at 
build-up region and in particular the surface dose on a plastic 
waterTM phantom for 6 and 15 MV photon beams from a Varian 
Clinac 2100 C/D, 10 x 10 cm2 field-size and SSD=100 cm. The 
percentage depth-dose distributions were measured with 
EBT2 films and Exradin W1 scintillator detector. The phantom 
consisted of 30× 30 cm2 slabs with thicknesses ranging from 
0.1 to 5 cm. In all cases, for each depth at least three 
measurements were taken and the experimental set-up was 
repeated in three different days. Regarding the EC 
measurements, a special support made of wood was 
constructed and successive depths were measured by adding 
the corresponding plastic water slabs over the entrance 
window of the chamber while fixing the SSD to 100 cm. For 
three electrode separations, three measurements were made 
at the positive and negative voltage bias and the 
corresponding average was calculated. 
Results: Monte Carlo simulation results were in good 
agreement with the EC measurements (average differences < 
2 %). Among the tested detectors, ultrathin TLD’s showed the 
best accuracy for surface dose estimations (within statistical 
uncertainties, 3% 1 SD). The correction factors for surface 
dose determination with the other detector types ranged 
from 0.3 to 0.8. Regarding dose measurements in the build-
up zone, Gafchromic films results were in good agreement 
with the EC measurements (average differences <2 %) with 
the exception of the surface dose. As expected due to its 
effective point of measurement, the Exradin W1 
overestimated the surface dose and its results were in 
agreement with the EC measurements (within 5%) for depths 
beyond 5 mm. 
Conclusions: Although extrapolation chambers are the most 
suited detectors for build-up measurements for megavoltage 
photon beams their use is not practical. Among the tested 
detectors, ultrathin TLD’s and Gafchromic films showed a 
good accuracy for dose measurements in the build-up zone. 
In particular, ultrathin TL detectors are the detector of 
choice for surface dose measurements. 
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Purpose/Objective: The goal of real-time 3D in vivo 
dosimetry, which we are currently capable of, is to prevent 
serious injuries to patients during radiotherapy by 
automatically halting the linac in case of uncorrectable dose 
deviations. These are, however, not well-defined. This study 
is exploring a new way of dose verification, called hot-spot 
analysis (HSA), which has been directly derived from a 
possible definition of an uncorrectable dose deviation. The 
parameters and alert criteria for HSA are of paramount 
importance: false positives would be detrimental to 
treatment throughput and may cause anxiety. False 
negatives, on the other hand, would defeat the purpose of 
real-time verification. By retrospectively analysing a large 
number of in vivo dosimetry measurements using HSA, we 
aim to determine its usefulness for clinical implementation of 
real-time 3D dosimetry at various alert levels. Note that real-
time dosimetry is not intended to find smaller, correctable 
deviations. 
Materials and Methods: An uncorrectable dose deviation is 
defined as a local overdose which would induce unacceptable 
toxicity to the patient. Note that it is not assumed that the 
patient’s setup is correct; hence, any such local overdose is 
regarded as an uncorrectable dose deviation regardless its 
actual position. In accordance with this definition, HSA seeks 
hot spots in the delivered dose distribution, defining a hot 
spot to be a volume with a certain minimum diameter and a 
minimum local overdose (MLO) within a region of interest 
(ROI) – the volume enclosed by a predefined isodose level in 
the delivered dose.  
In this study, a minimum diameter of a hot spot of 17 mm, 
corresponding to a volume of 5cc, was used and two ROIs 
were evaluated: defined by the 1 and 2 Gy isodose surfaces. 
To obtain insight in the distribution of deviations, the 
threshold MLO is varied from 2 – 100%, allowing in the most 
extreme case a single-fraction overdosage of 4 Gy. HSA was 
then used to re-analyse reconstructed 3D dose distributions 
of 1095 randomly selected incident-free treatments given in 
2013, all of which had been verified (offline) using our 3D 
EPID-based in vivo dosimetry method. For each treatment 
and each set of HSA parameters, the presence of hot spots 
was determined. 
Results: Table 1 shows for both ROIs the number of 
treatments having at least one hot spot as a function of 
threshold MLO; the distribution of positive alerts is clearly 
not normal. Individual inspection of these alerts is ongoing, 
but seems to indicate that either they are not big enough to 
be considered as an incident alert, e.g. for the low MLO 
values, or are caused by limitations of our 3D dose 
reconstruction model. 
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Conclusions: HSA is a useful method for detecting 
uncorrectable dose deviations derived from a clear clinical 
motivation. As such, it is a promising method for detecting 
deviations relevant to real-time dosimetry. However, the 
current number of false alerts is still too high for direct 
clinical implementation.  
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Purpose/Objective: Entrance dose in vivo dosimetry (IVD) 
using diodes is an end-to-end QA procedure that is widely 
used in conventional radiotherapy treatments. However, in 
advanced delivery techniques, such as SIB-IMRT, the 
reliability of this QA procedure is controversial. We 
developed a reliable QA procedure for breast treatments 
delivered using a SIB-IMRT technique based on IVD using 
diodes. 
Materials and Methods: We calibrated 6-12 MV QED diodes 
(Sun Nuclear) using an emX electrometer (IBA) in terms of 
entrance dose at SSD = 90 cm and field size = 10 cm x 20 cm 
(average conditions for IMRT breast treatments). We 
measured correction factors for distance, field size, 
obliquity, and MLC transmission. We planned 14 SIB breast 
treatments using 6MV x-rays and 7-9 sliding window IMRT 
fields (TPS: Eclipse, algorithm: AAA v8.9; Varian). 
Determining entrance dose points is challenging due to 
fluence modulation, and also to patient contour 
irregularities, beam obliquity and tissue heterogeneities. To 
minimize these challenges, we calculated all treatment fields 
at 0º gantry angle, maintaining the SSD, on a regular water 
phantom. For each field, we recorded entrance dose (at 
maximum dose depth) at two points: on the central axis and 
on the region of highest fluence. Treatments were performed 
using a Clinac 2100C/D equipped with a Millenium 120 MLC 
and the RPM system (Varian) for respiratory motion 
management. We placed one diode at each of the 
aforementioned points on the patients' skin. We assessed 
clinical uncertainties by placing the diodes at the same 
position but on a Plastic Water phantom (CIRS), and 
irradiating them under the conditions used for entrance dose 
calculations. To ensure positioning accuracy was lower than 
0.5 cm, we attached a template which projected a 1 cm 
square grid at isocenter to the collimator using an add-on. 
We compared IVD measurements with the calculated 
entrance doses. 
Results: The table shows the average difference between 
measurements and calculations, excluding doses below fixed 
thresholds. Consistency improved by increasing the threshold 
because we excluded false positives due to non-significant 
dose contributions. Although agreement between in-phantom 
measurements and calculations was excellent, in patients we 
observed larger differences and variability due to positioning 
inaccuracies (figure). The table shows the two-fold 
tolerances which provided >95% of acceptable IVD 
assessments. 
 
 
 
 
Conclusions: IVD using diodes is a feasible QA procedure for 
breast treatments delivered using a SIB-IMRT technique. We 
propose using two diodes per field in high-fluence regions 
(entrance dose >0.2 Gy). We suggest a two-fold tolerance for 
IVD assessment (95% confidence limits): a dose difference of 
15% for both diodes per field, and an average difference of 
3.6% including all measurements per patient. 
This work was funded by grant Barcelona Board of the 
Spanish Association Against Cancer (AECC) 2012. 
 
PO-0845   
Development of methodology for remote IMRT audits and 
related tests 
D. Georg1,2, G. Azangwe3, D. Followill4, P. Grochowska3, S. 
Kry4, W. Lechner1,2, J. Povall5, M. Tenhunen6, D.I. Thwaites7, 
M. Tomsej8, J. Izewska3 
1Medical University of Vienna AKH Wien, Radiation Oncology, 
Vienna, Austra  
2Christian Doppler Laboratory for Medical Radiation Research 
for Radiation Oncology, Vienna, Austria  
3International Atomic Energy Agency, Division of Human 
Health, Vienna, Austria  
4IROC Houston QA Center, U.T. M. D. Anderson Cancer 
Centre, Houston, USA  
5St. James's Institute of Oncology University of Leeds, 
Radiotherapy Physics Group, Leeds, United Kingdom  
6Helsinki University Central Hospital, Department of 
Oncology, Helsinki, Finland  
7School of Physics University of Sydney, Institute of Physics, 
Sydney, Australia  
8University Hospital Charleroi, Department of Radiation 
Oncology, Charleroi, Belgium  
 
Purpose/Objective: A co-ordinated research project (CRP) is 
under development and implementation within a 
collaborative multi-centre effort. The aim of the CRP is to 
broaden the portfolio of dosimetry audits offered to 
radiotherapy centres by national audit networks operating in 
middle and low income countries. Moreover, the inclusion of 
